Prostatype Genomics AB (OSTO:PROGEN) Interest Expense: kr-1.62 Mil (TTM As of Dec. 2025)


OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
25 GF Score
Price kr0.33
GF Value kr0.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Interest Expense?

Prostatype Genomics AB OSTO:PROGEN -8.33% 25 Interest Expense is kr-1.62 Mil as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Prostatype Genomics AB's interest expense for the six months ended in Dec. 2025 was kr -1.39 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr-1.62 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Prostatype Genomics AB's Operating Income for the six months ended in Dec. 2025 was kr -18.87 Mil. Prostatype Genomics AB's Interest Expense for the six months ended in Dec. 2025 was kr -1.39 Mil. Prostatype Genomics AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Prostatype Genomics AB  (OSTO:PROGEN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Prostatype Genomics AB's Interest Expense for the six months ended in Dec. 2025 was kr-1.39 Mil. Its Operating Income for the six months ended in Dec. 2025 was kr-18.87 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was kr0.00 Mil.

Prostatype Genomics AB's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Prostatype Genomics AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Prostatype Genomics AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Interest Expense Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.08 -0.40 -1.54 -1.68 -1.62

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.50 -0.83 -0.85 -0.23 -1.39
OSTO:PROGEN
25GF Score
Prostatype Genomics AB OSTO:PROGEN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-1.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-1.62 Mil mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Interest Expense of kr-1.62 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Interest Expense too high?
Prostatype Genomics AB's current Interest Expense is kr-1.62 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Interest Expense compare to TMO and DHR?
Prostatype Genomics AB's Interest Expense of kr-1.62 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Diagnostics & Research company?
A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Interest Expense is kr-1.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.33 — trading 200% above its estimated fair value. The current Interest Expense is kr-1.62 Mil. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Interest Expense is kr-1.62 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.33 is trading 200% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Interest Expense: kr-1.62 Mil
  • GF Value™: kr0.11 vs. price of kr0.33 (200% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for OSTO:PROGEN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.33
Price
kr0.11
GF Value